BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10194544)

  • 1. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
    Ferrari S; Pieretti F; Verri E; Tolentinis L; Cesari M; Versari M; Zolezzi C; Lamanna G; Bacci G
    Anticancer Drugs; 2005 Aug; 16(7):733-8. PubMed ID: 16027521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
    Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
    Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
    Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
    Caglar M; Yarís N; Akyuz C
    Nucl Med Commun; 2001 Dec; 22(12):1325-32. PubMed ID: 11711903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
    Rossi RM; Kist C; Wurster U; Külpmann WR; Ehrich JH
    Pediatr Nephrol; 1994 Apr; 8(2):151-6. PubMed ID: 8018491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
    Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Longhi A; Macchiagodena M; Vitali G; Bacci G
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):292-6. PubMed ID: 12679642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series.
    Palmerini E; Setola E; Grignani G; D'Ambrosio L; Comandone A; Righi A; Longhi A; Cesari M; Paioli A; Hakim R; Pierini M; Marchesi E; Vanel D; Pignochino Y; Donati DM; Picci P; Ferrari S
    Cells; 2020 Oct; 9(11):. PubMed ID: 33142760
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Canpolat C; Pearson P; Robertson R; Jaffe N
    Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
    J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.